Table 7 Ongoing or completed clinical trials of CAR-NK therapies
NCT number | CAR target | NK cell source | Targeting tumor | Phase | Status |
|---|---|---|---|---|---|
NCT03056339 | CD19 | UCB | Hematological malignancies | 1/2 | Completed |
NCT05563545 | CD19 | Non-referred | ALL | 1 | Completed |
NCT05654038 | CD19 | HPCs | B-cell lymphoma | 1/2 | Recruiting |
NCT05092451 | CD70 | UCB | Hematological malignancies | 1/2 | Recruiting |
NCT05703854 | CD70 | UCB | Solid tumors | 1/2 | Recruiting |
NCT05842707 | CD19/CD70 | UCB | B-cell NHL | 1/2 | Recruiting |
NCT05410717 | Claudin6 | PBMCs | Reproductive system tumors | 1/2 | Recruiting |
NCT04847466 | PD-L1 | NK92 | GEJ cancers or HNSCC | 2 | Recruiting |
NCT05472558 | CD19 | UCB | B-cell NHL | 1 | Recruiting |
NCT04887012 | CD19 | Non-referred | B-cell NHL | 1 | Recruiting |
NCT05213195 | NKG2D | Non-referred | Colorectal cancer | 1 | Recruiting |
NCT05528341 | NKG2D | NK92 | Solid Tumors | 1 | Recruiting |
NCT05645601 | CD19 | Non-referred | Hematological Malignancies | 1 | Recruiting |
NCT05008575 | CD33 | Non-referred | AML | 1 | Recruiting |
NCT05507593 | DLL3 | NK92 | Extensive-stage SCLC | 1 | Recruiting |
NCT05410041 | CD19 | Non-referred | Hematological Malignancies | 1 | Recruiting |
NCT04623944 | NKG2D ligands | Non-referred | Hematological Malignancies | 1 | Recruiting |
NCT05020678 | CD19 | Non-referred | Hematological Malignancies | 1 | Recruiting |
NCT05667155 | CD19/CD70 | UCB | B-cell NHL | 1 | Recruiting |
NCT04796675 | CD19 | UCB | Hematological Malignancies | 1 | Recruiting |
NCT05665075 | CD33 | iPSC | AML | 1 | Recruiting |
NCT05601466 | CD33 | iPSC | AML | 1 | Recruiting |
NCT05379647 | CD19 | iPSC | B-cell Malignancies | 1 | Recruiting |
NCT05182073 | BCMA | iPSC | Multiple myeloma | 1 | Recruiting |
NCT05336409 | CD19 | iPSC | Hematological Malignancies | 1 | Recruiting |
NCT03383978 | HER2 | NK92 | Glioblastoma | 1 | Recruiting |